Lv1
30 积分 2022-12-09 加入
Antibody–oligonucleotide conjugates enter the clinic
2个月前
已完结
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
4个月前
已完结
Now with oligos: antibody–oligonucleotide conjugates are the new drug modality to watch
4个月前
已完结
Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment
5个月前
已完结
Innovative antibody therapeutic development in China compared with the USA and Europe
5个月前
已完结
Development Strategy for Innovation System of Radiopharmaceuticals in China
6个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
8个月前
已完结
The rise of China’s pharmaceutical industry from 2015–2024: a decade of innovation
9个月前
已完结
The impact of external innovation on new drug approvals: A retrospective analysis
9个月前
已完结
The Withdrawal of Drugs for Commercial Reasons
9个月前
已完结
皖公网安备34019202002308
